Class information for:
Level 1: PITAVASTATIN//NK 104//CAS 147526 32 7

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
18626 543 39.0 85%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
171 3       MONASCUS//CITRININ//MONASCUS PURPUREUS 58457
419 2             STATINS//EZETIMIBE//SIMVASTATIN 16502
18626 1                   PITAVASTATIN//NK 104//CAS 147526 32 7 543

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PITAVASTATIN authKW 1831823 14% 42% 77
2 NK 104 authKW 678816 2% 93% 13
3 CAS 147526 32 7 authKW 455489 2% 90% 9
4 TOKYO NEW DRUG S 1 address 239922 1% 53% 8
5 STATINS authKW 219050 31% 2% 169
6 PITAVASTATIN CALCIUM authKW 184031 1% 55% 6
7 MONOCALCIUM BIS3R 5S 6E 7 2 CYCLOPROPYL 4 4 FLUOROPHENYL 3 QUINOLYL 3 5 DIHYDROXY 6 HEPTENOATE authKW 168700 1% 100% 3
8 ARTERIOSCLEROT METAB MED address 112467 0% 100% 2
9 HIGH INTENSITY STATINS authKW 112467 0% 100% 2
10 IR DEPENDENT IRS 1 PI3K AKT PATHWAY authKW 112467 0% 100% 2

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Cardiac & Cardiovascular System 1721 23% 0% 124
2 Endocrinology & Metabolism 1647 22% 0% 119
3 Peripheral Vascular Diseases 1275 15% 0% 80
4 Pharmacology & Pharmacy 792 24% 0% 130
5 Medicine, General & Internal 243 11% 0% 61
6 Medicine, Research & Experimental 74 6% 0% 30
7 Chemistry, Medicinal 34 3% 0% 17
8 Toxicology 9 2% 0% 11
9 Nutrition & Dietetics 8 2% 0% 9
10 Chemistry, Analytical 5 3% 0% 16

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 TOKYO NEW DRUG S 1 239922 1% 53% 8
2 ARTERIOSCLEROT METAB MED 112467 0% 100% 2
3 NUCLEO INVEST ARTERIAL 74977 0% 67% 2
4 SHIRAOKA STN BIOL SCI 67470 1% 20% 6
5 BUCKINGHAM COURT 56233 0% 100% 1
6 CARDIOLUNION HOSPMINIST EDUC 56233 0% 100% 1
7 CARDIOVASC MED FALK CVRC 56233 0% 100% 1
8 CHOLESTEROL TREATMENT TRIALISTS ABORAT 56233 0% 100% 1
9 CLIN BIOL 2 56233 0% 100% 1
10 DIABET CLIN SCI MALMOSUS MALMO 56233 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ATHEROSCLEROSIS SUPPLEMENTS 16426 2% 3% 9
2 JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS 11318 3% 1% 15
3 CLINICAL LIPIDOLOGY 7199 1% 2% 7
4 ATHEROSCLEROSIS 4428 5% 0% 29
5 JOURNAL OF DIABETES INVESTIGATION 1568 1% 1% 4
6 CURRENT OPINION IN LIPIDOLOGY 1517 1% 0% 6
7 CURRENT ATHEROSCLEROSIS REPORTS 1353 1% 1% 4
8 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 1300 1% 0% 7
9 AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 1196 1% 1% 3
10 CARDIOVASCULAR DIABETOLOGY 1128 1% 0% 5

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PITAVASTATIN 1831823 14% 42% 77 Search PITAVASTATIN Search PITAVASTATIN
2 NK 104 678816 2% 93% 13 Search NK+104 Search NK+104
3 CAS 147526 32 7 455489 2% 90% 9 Search CAS+147526+32+7 Search CAS+147526+32+7
4 STATINS 219050 31% 2% 169 Search STATINS Search STATINS
5 PITAVASTATIN CALCIUM 184031 1% 55% 6 Search PITAVASTATIN+CALCIUM Search PITAVASTATIN+CALCIUM
6 MONOCALCIUM BIS3R 5S 6E 7 2 CYCLOPROPYL 4 4 FLUOROPHENYL 3 QUINOLYL 3 5 DIHYDROXY 6 HEPTENOATE 168700 1% 100% 3 Search MONOCALCIUM+BIS3R+5S+6E+7+2+CYCLOPROPYL+4+4+FLUOROPHENYL+3+QUINOLYL+3+5+DIHYDROXY+6+HEPTENOATE Search MONOCALCIUM+BIS3R+5S+6E+7+2+CYCLOPROPYL+4+4+FLUOROPHENYL+3+QUINOLYL+3+5+DIHYDROXY+6+HEPTENOATE
7 HIGH INTENSITY STATINS 112467 0% 100% 2 Search HIGH+INTENSITY+STATINS Search HIGH+INTENSITY+STATINS
8 IR DEPENDENT IRS 1 PI3K AKT PATHWAY 112467 0% 100% 2 Search IR+DEPENDENT+IRS+1+PI3K+AKT+PATHWAY Search IR+DEPENDENT+IRS+1+PI3K+AKT+PATHWAY
9 PITAVASTATIN LACTONE 112467 0% 100% 2 Search PITAVASTATIN+LACTONE Search PITAVASTATIN+LACTONE
10 HMG COA REDUCTASE INHIBITORS 86854 7% 4% 40 Search HMG+COA+REDUCTASE+INHIBITORS Search HMG+COA+REDUCTASE+INHIBITORS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 CEDERBERG, H , STANCAKOVA, A , YALURI, N , MODI, S , KUUSISTO, J , LAAKSO, M , (2015) INCREASED RISK OF DIABETES WITH STATIN TREATMENT IS ASSOCIATED WITH IMPAIRED INSULIN SENSITIVITY AND INSULIN SECRETION: A 6 YEAR FOLLOW-UP STUDY OF THE METSIM COHORT.DIABETOLOGIA. VOL. 58. ISSUE 5. P. 1109 -1117 22 85% 53
2 BETTERIDGE, DJ , CARMENA, R , (2016) THE DIABETOGENIC ACTION OF STATINS - MECHANISMS AND CLINICAL IMPLICATIONS.NATURE REVIEWS ENDOCRINOLOGY. VOL. 12. ISSUE 2. P. 99 -110 40 49% 5
3 KOSTAPANOS, MS , LIAMIS, GL , MILIONIS, HJ , ELISAF, MS , (2010) DO STATINS BENEFICIALLY OR ADVERSELY AFFECT GLUCOSE HOMEOSTASIS?.CURRENT VASCULAR PHARMACOLOGY. VOL. 8. ISSUE 5. P. 612-631 61 46% 32
4 ARNABOLDI, L , CORSINI, A , (2015) COULD CHANGES IN ADIPONECTIN DRIVE THE EFFECT OF STATINS ON THE RISK OF NEW-ONSET DIABETES? THE CASE OF PITAVASTATIN.ATHEROSCLEROSIS SUPPLEMENTS. VOL. 16. ISSUE . P. 1 -27 78 27% 8
5 AGOURIDIS, AP , KOSTAPANOS, MS , ELISAF, MS , (2015) STATINS AND THEIR INCREASED RISK OF INDUCING DIABETES.EXPERT OPINION ON DRUG SAFETY. VOL. 14. ISSUE 12. P. 1835 -1844 40 55% 3
6 FILIPPATOS, TD , ELISAF, MS , (2016) PITAVASTATIN AND CARBOHYDRATE METABOLISM: WHAT IS THE EVIDENCE?.EXPERT REVIEW OF CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 7. P. 955 -960 31 67% 0
7 BARYLSKI, M , NIKOLIC, D , BANACH, M , TOTH, PP , MONTALTO, G , RIZZO, M , (2014) STATINS AND NEW-ONSET DIABETES.CURRENT PHARMACEUTICAL DESIGN. VOL. 20. ISSUE 22. P. 3657 -3664 34 60% 5
8 ROBINSON, JG , (2015) STATINS AND DIABETES RISK: HOW REAL IS IT AND WHAT ARE THE MECHANISMS?.CURRENT OPINION IN LIPIDOLOGY. VOL. 26. ISSUE 3. P. 228 -235 23 77% 6
9 MUSCOGIURI, G , SARNO, G , GASTALDELLI, A , SAVASTANO, S , ASCIONE, A , COLAO, A , ORIO, F , (2014) THE GOOD AND BAD EFFECTS OF STATINS ON INSULIN SENSITIVITY AND SECRETION.ENDOCRINE RESEARCH. VOL. 39. ISSUE 4. P. 137 -143 31 62% 3
10 KOH, KK , SAKUMA, I , QUON, MJ , (2011) DIFFERENTIAL METABOLIC EFFECTS OF DISTINCT STATINS.ATHEROSCLEROSIS. VOL. 215. ISSUE 1. P. 1 -8 35 49% 58

Classes with closest relation at Level 1


Rank Class id link
1 413 STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN
2 7494 STATINS//RHABDOMYOLYSIS//STATIN INTOLERANCE
3 9366 PCSK9//PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9//ALIROCUMAB
4 2292 STATINS//ATORVASTATIN//HMG COA REDUCTASE INHIBITORS
5 13608 EZETIMIBE//NPC1L1//CHOLESTEROL ABSORPTION INHIBITOR
6 10374 FENOFIBRATE//FENOFIBRIC ACID//FIBRATES
7 5456 OATP1B1//SLCO1B1//OATP
8 23438 BILE ACID SEQUESTRANT//COLESEVELAM HCL//COLESEVELAM
9 18946 ATORVASTATIN CALCIUM//EZETIMIBE//ROSUVASTATIN CALCIUM
10 9257 PRAVASTATIN//HMG COA REDUCTASE INHIBITORS//MEVALONIC ACID

Go to start page